VVP
ADCT icon

Venture Visionary Partners’s ADC Therapeutics ADCT Stock Holding History

Venture Visionary Partners’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-100
Closed -$795 – 474
2022
Q2 		$795 Buy
+100
New +$946 ﹤0.01% 1624

Other funds holding ADCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
GGH
GCM Grosvenor Holdings Chicago, Illinois $901M AUM 28.6% 1-Year Est. Return

Venture Visionary Partners's ADCT Position: Q3 2022 in Review

Venture Visionary Partners sold out of ADC Therapeutics (ADCT) in Q3 2022, closing a stake of 100 shares — an estimated $795 sold.

Venture Visionary Partners first reported a position in ADCT in Q2 2022 and held it in 1 quarter. The position peaked at $795 in Q2 2022. 66 funds tracked by Wall St. Rank hold ADCT as of Q3 2022.

  • Venture Visionary Partners reported no remaining ADC Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Venture Visionary Partners sold 100 ADC Therapeutics shares in Q3 2022, an estimated $795.
  • Venture Visionary Partners first reported a position in ADC Therapeutics in Q2 2022 and held it in 1 quarter.
  • Venture Visionary Partners's ADC Therapeutics position peaked at $795 in Q2 2022.
  • 66 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2022.

Based on Venture Visionary Partners's 13F filing for Q3 2022, filed 14 Nov 2022.